Inhibition of prostate cancer growth by estramustine and etoposide
- 1 April 1995
- Vol. 75 (S7) , 1920-1926
- https://doi.org/10.1002/1097-0142(19950401)75:7+<1920::aid-cncr2820751627>3.0.co;2-y
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Oral etoposide in the treatment of hormone-refractory prostate cancerCancer, 1994
- Inhibition of Prostate Cancer Growth by Estramustineand Etoposide: Evidence For Interaction at the Nuclear MatrixJournal of Urology, 1993
- A common set of nuclear matrix proteins in prostate cancer cellsThe Prostate, 1993
- Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1992
- Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSABiochemistry, 1990
- Comparison of flutamide and emcyt in hormone-refractory metastatic prostatic cancerUrology, 1988
- Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustineUrological Research, 1987
- THE ROLE OF THE NUCLEAR MATRIX IN THE ORGANIZATION AND FUNCTION OF DNAAnnual Review of Biophysics, 1986
- A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.Journal of Clinical Oncology, 1985
- Use of estramustine phosphate in prostate cancer by the National Prostatic Cancer Project and by Roswell Park Memorial InstituteUrology, 1984